This position paper incorporates the most recent developments in the field of measles and includes removal of introduction criteria for the routine second dose of measles-containing vaccine (MCV2), guidance on when to vaccinate infants from 6 months of age, and guidance on re-vaccination of HIV-infected children receiving highly active anti-retroviral therapy (HAART). It replaces the 2009 WHO position paper on measles vaccines.
Recommendations on the use of measles vaccines were last discussed by SAGE in November 2013, October 2015 and October 2016; evidence presented at these meetings can be accessed at: www.who.int/immunization/sage/meetings/2013/november/presentations_background_docs/en/,
www.who.int/immunization/sage/meetings/2015/october/presentations_background_docs/en/
and www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/.
- Position paper
- Measles
